Andrew Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7076354/publications.pdf Version: 2024-02-01



ANDREW MANC

#	Article	IF	CITATIONS
1	Delivery strategies to overcome tumor immunotherapy resistance. , 2022, , 529-547.		0
2	Nanoparticle Delivery of miR-122 Inhibits Colorectal Cancer Liver Metastasis. Cancer Research, 2022, 82, 105-113.	0.9	21
3	Immune Checkpoint Ligand Bioengineered Schwann Cells as Antigenâ€Specific Therapy for Experimental Autoimmune Encephalomyelitis. Advanced Materials, 2022, 34, e2107392.	21.0	7
4	Immune Checkpoint Ligand Bioengineered Schwann Cells as Antigenâ€5pecific Therapy for Experimental Autoimmune Encephalomyelitis (Adv. Mater. 5/2022). Advanced Materials, 2022, 34, .	21.0	0
5	3D printed drug-loaded implantable devices for intraoperative treatment of cancer. Journal of Controlled Release, 2022, 344, 147-156.	9.9	10
6	Radiosensitivity of Breast Cancer Cells Is Dependent on the Organ Microenvironment. Frontiers in Oncology, 2022, 12, .	2.8	1
7	Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis. Biosensors and Bioelectronics, 2022, 213, 114445.	10.1	14
8	Continuous liquid interface production of 3D printed drug-loaded spacers to improve prostate cancer brachytherapy treatment. Acta Biomaterialia, 2022, 148, 163-170.	8.3	2
9	Quality-of-life Benefits and Harms from Prostate Radiotherapy in Patients with Low-burden Metastatic Prostate Cancer. European Urology, 2021, 79, 198-199.	1.9	0
10	The Radiobiology of Radiopharmaceuticals. Seminars in Radiation Oncology, 2021, 31, 20-27.	2.2	21
11	Consolidative or palliative whole brain radiation for secondary CNS diffuse large B-Cell lymphoma. Leukemia and Lymphoma, 2021, 62, 68-75.	1.3	4
12	COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. Journal of Hematology and Oncology, 2021, 14, 38.	17.0	87
13	Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models. Acta Biomaterialia, 2021, 124, 327-335.	8.3	34
14	Immune Checkpointâ€Bioengineered Beta Cell Vaccine Reverses Earlyâ€Onset Type 1 Diabetes. Advanced Materials, 2021, 33, e2101253.	21.0	16
15	Underascertainment of Clinically Meaningful Symptoms During Prostate Cancer Radiation Therapy—Does This Vary by Patient Characteristics?. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1122-1128.	0.8	3
16	Asymmetric multi-task attention network for prostate bed segmentation in computed tomography images. Medical Image Analysis, 2021, 72, 102116.	11.6	14
17	Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics. Neoplasia, 2021, 23, 851-858.	5.3	31
18	Prognostic and Predictive Clinical and Biological Factors in HPV Malignancies. Seminars in Radiation Oncology, 2021, 31, 309-323.	2.2	0

#	Article	IF	CITATIONS
19	A Tribute to Dr Larissa Lee. Practical Radiation Oncology, 2021, , .	2.1	2
20	<i>In Vivo</i> Bioengineering of Beta Cells with Immune Checkpoint Ligand as a Treatment for Early-Onset Type 1 Diabetes Mellitus. ACS Nano, 2021, 15, 19990-20002.	14.6	12
21	Dosimetric correlations with urinary quality of life in patients receiving post-prostatectomy radiation therapy. Journal of Radiation Oncology, 2020, 9, 97-102.	0.7	Ο
22	Enhancing Combined Immunotherapy and Radiotherapy through Nanomedicine. Bioconjugate Chemistry, 2020, 31, 2668-2678.	3.6	13
23	Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment. Acta Pharmacologica Sinica, 2020, 41, 970-985.	6.1	49
24	Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy. Science Advances, 2020, 6, eaba8564.	10.3	66
25	Nanoparticle Drug Delivery Can Reduce the Hepatotoxicity of Therapeutic Cargo. Small, 2020, 16, 1906360.	10.0	16
26	Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application. Biosensors and Bioelectronics, 2020, 162, 112250.	10.1	27
27	Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation. Nature Communications, 2020, 11, 1750.	12.8	67
28	Pretargeted delivery of PI3K/mTOR small-molecule inhibitor–loaded nanoparticles for treatment of non-Hodgkin's lymphoma. Science Advances, 2020, 6, eaaz9798.	10.3	30
29	Asymmetrical Multi-task Attention U-Net for the Segmentation of Prostate Bed in CT Image. Lecture Notes in Computer Science, 2020, 12264, 470-479.	1.3	9
30	Biologically Targeted Photoâ€Crosslinkable Nanopatch to Prevent Postsurgical Peritoneal Adhesion. Advanced Science, 2019, 6, 1900809.	11.2	10
31	Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy. Advanced Drug Delivery Reviews, 2019, 144, 3-15.	13.7	44
32	Nanomedicine: Biologically Targeted Photo rosslinkable Nanopatch to Prevent Postsurgical Peritoneal Adhesion (Adv. Sci. 19/2019). Advanced Science, 2019, 6, 1970117.	11.2	1
33	Phase I/II trial of nano-camptothecin CRLX101 with capecitabine and radiotherapy as neoadjuvant treatment for locally advanced rectal cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 18, 189-195.	3.3	37
34	Emerging Nano″Microapproaches for Cancer Immunotherapy. Advanced Science, 2019, 6, 1801847.	11.2	136
35	Nanotechnology in Radiation Oncology. Hematology/Oncology Clinics of North America, 2019, 33, 1071-1093.	2.2	12
36	High-Performance Concurrent Chemo-Immuno-Radiotherapy for the Treatment of Hematologic Cancer through Selective High-Affinity Ligand Antibody Mimic-Functionalized Doxorubicin-Encapsulated Nanoparticles. ACS Central Science, 2019, 5, 122-144.	11.3	28

#	Article	IF	CITATIONS
37	Co-delivery of paclitaxel and cisplatin in poly(2-oxazoline) polymeric micelles: Implications for drug loading, release, pharmacokinetics and outcome of ovarian and breast cancer treatments. Biomaterials, 2019, 192, 1-14.	11.4	158
38	Cardiovascular Preventive Care and Coordination of Care in Prostate Cancer Survivors: A Multi-Institutional Prospective Study. International Journal of Radiation Oncology Biology Physics, 2019, 103, 112-115.	0.8	14
39	Abstract 3899: Nanoparticle reduces hepatotoxicity of cancer treatment by controlled release and Kupffer cell uptake. Cancer Research, 2019, 79, 3899-3899.	0.9	2
40	Gender-Specific Relationship Between Uric Acid Levels and Prognosis After Cerebral Venous Thrombosis. Current Neurovascular Research, 2019, 15, 292-297.	1.1	2
41	Abstract 410: Quantification and downstream analysis of circulating tumor cells isolated using CapioCyteTMliquid biopsy. , 2019, , .		Ο
42	Organ-specific metastases obtained by culturing colorectal cancer cells on tissue-specific decellularized scaffolds. Nature Biomedical Engineering, 2018, 2, 443-452.	22.5	73
43	A Dual Immunotherapy Nanoparticle Improves T ell Activation and Cancer Immunotherapy. Advanced Materials, 2018, 30, e1706098.	21.0	130
44	Clinical indications for, and the future of, circulating tumor cells. Advanced Drug Delivery Reviews, 2018, 125, 143-150.	13.7	57
45	A prospective study of the safety and efficacy of liver stereotactic body radiotherapy in patients with and without prior liver-directed therapy. Radiotherapy and Oncology, 2018, 126, 527-533.	0.6	37
46	Tuning Pt–Ir Interactions for NH ₃ Electrocatalysis. ACS Catalysis, 2018, 8, 2508-2518.	11.2	46
47	Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma. ACS Nano, 2018, 12, 1544-1563.	14.6	38
48	Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care. ACS Nano, 2018, 12, 24-43.	14.6	192
49	Nanoparticle co-delivery of wortmannin and cisplatin synergistically enhances chemoradiotherapy and reverses platinum resistance in ovarian cancer models. Biomaterials, 2018, 169, 1-10.	11.4	65
50	Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture. Clinical Cancer Research, 2018, 24, 2539-2547.	7.0	32
51	Controlling release from 3D printed medical devices using CLIP and drug-loaded liquid resins. Journal of Controlled Release, 2018, 278, 9-23.	9.9	73
52	Drug Combination Synergy in Worm-like Polymeric Micelles Improves Treatment Outcome for Small Cell and Non-Small Cell Lung Cancer. ACS Nano, 2018, 12, 2426-2439.	14.6	132
53	Enhanced electrocatalytic nitrate reduction by preferentially-oriented (100) PtRh and PtIr alloys: the hidden treasures of the â€~miscibility gap'. Applied Catalysis B: Environmental, 2018, 221, 86-96.	20.2	44
54	Integration of biomimicry and nanotechnology for significantly improved detection of circulating tumor cells (CTCs). Advanced Drug Delivery Reviews, 2018, 125, 36-47.	13.7	23

#	Article	IF	CITATIONS
55	Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience. Frontiers in Oncology, 2018, 8, 544.	2.8	11
56	Fitting NTCP models to bladder doses and acute urinary symptoms during post-prostatectomy radiotherapy. Radiation Oncology, 2018, 13, 17.	2.7	15
57	Nanotechnology enabling the use of circulating tumor cells (CTCs) as reliable cancer biomarkers. Advanced Drug Delivery Reviews, 2018, 125, 1-2.	13.7	7
58	Combination Immunotherapy: A Dual Immunotherapy Nanoparticle Improves T ell Activation and Cancer Immunotherapy (Adv. Mater. 25/2018). Advanced Materials, 2018, 30, 1870182.	21.0	4
59	Nanotechnology Approaches to Improving Cancer Immunotherapy. Advances in Cancer Research, 2018, 139, 35-56.	5.0	33
60	Abstract 5702: Characterization of circulating tumor cells during immune checkpoint inhibition in metastatic renal cell carcinoma and malignant melanoma. , 2018, , .		0
61	Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2017, 9, e1416.	6.1	299
62	Bio-nano interface: The impact of biological environment on nanomaterials and their delivery properties. Journal of Controlled Release, 2017, 263, 211-222.	9.9	57
63	Nanomedicine approaches to improve cancer immunotherapy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2017, 9, e1456.	6.1	39
64	Co-delivery of all-trans-retinoic acid enhances the anti-metastasis effect of albumin-bound paclitaxel nanoparticles. Chemical Communications, 2017, 53, 212-215.	4.1	26
65	Effect of particle size on the biodistribution, toxicity, and efficacy of drug-loaded polymeric nanoparticles in chemoradiotherapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1673-1683.	3.3	78
66	Applying nanotherapeutics to improve chemoradiotherapy treatment for cancer. Therapeutic Delivery, 2017, 8, 791-803.	2.2	11
67	LiGa ₅ O ₈ :Cr-based theranostic nanoparticles for imaging-guided X-ray induced photodynamic therapy of deep-seated tumors. Materials Horizons, 2017, 4, 1092-1101.	12.2	128
68	Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nature Nanotechnology, 2017, 12, 877-882.	31.5	541
69	Co-delivery of paclitaxel and cisplatin with biocompatible PLGA–PEG nanoparticles enhances chemoradiotherapy in non-small cell lung cancer models. Journal of Materials Chemistry B, 2017, 5, 6049-6057.	5.8	53
70	CRLX101, a Nanoparticle–Drug Conjugate Containing Camptothecin, Improves Rectal Cancer Chemoradiotherapy by Inhibiting DNA Repair and HIF1α. Cancer Research, 2017, 77, 112-122.	0.9	60
71	Patient-reported quality of life during definitive and postprostatectomy image-guided radiation therapy for prostate cancer. Practical Radiation Oncology, 2017, 7, e117-e124.	2.1	10
72	Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 1301-1307.	3.3	19

#	Article	IF	CITATIONS
73	Phase Ib/II study of neoadjuvant chemoradiotherapy with CRLX101 and capecitabine for locally advanced rectal cancer Journal of Clinical Oncology, 2017, 35, e15144-e15144.	1.6	2
74	X-Ray Induced Photodynamic Therapy: A Combination of Radiotherapy and Photodynamic Therapy. Theranostics, 2016, 6, 2295-2305.	10.0	171
75	Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2016, 96, 547-555.	0.8	23
76	Prostate deformation from inflatable rectal probe cover and dosimetric effects in prostate seed implant brachytherapy. Medical Physics, 2016, 43, 6569-6576.	3.0	0
77	Application of nanotechnology to cancer radiotherapy. Cancer Nanotechnology, 2016, 7, 11.	3.7	125
78	Nanoparticle formulation of small DNA molecules, Dbait, improves the sensitivity of hormone-independent prostate cancer to radiotherapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 2261-2271.	3.3	21
79	Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma. Asian Journal of Urology, 2016, 3, 268-277.	1.2	4
80	Inflammationâ€Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Antiâ€PD1 Antibody. Advanced Materials, 2016, 28, 8912-8920.	21.0	286
81	Patterns of Bladder Preservation TherapyÂUtilization for Muscle-Invasive Bladder Cancer. Bladder Cancer, 2016, 2, 405-413.	0.4	12
82	Abstract 3954: Prospective evaluation of circulating tumor cells (CTCs) in head and neck cancer patients receiving definitive radiotherapy with a nanotechnology based system. , 2016, , .		0
83	IGF-1 receptor targeted nanoparticles for image-guided therapy of stroma-rich and drug resistant human cancer. , 2016, 9836, .		4
84	Accurate Segmentation of CT Male Pelvic Organs via Regression-Based Deformable Models and Multi-Task Random Forests. IEEE Transactions on Medical Imaging, 2016, 35, 1532-1543.	8.9	71
85	Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic. Biomaterials, 2016, 82, 178-193.	11.4	100
86	The mRNA "game changer―in gene therapy. Science Translational Medicine, 2016, 8, .	12.4	1
87	Bad plumbing benefits nanoparticles. Science Translational Medicine, 2016, 8, .	12.4	1
88	Abstract 4264: Engineered in vitro models of cancer metastasis using decellularized biomatrix. , 2016, ,		0
89	Technical Note: Fabricating Cerrobend grids with 3D printing for spatially modulated radiation therapy: A feasibility study. Medical Physics, 2015, 42, 6269-6273.	3.0	10
90	Direct Observation of Early-Stage High-Dose Radiotherapy-Induced Vascular Injury via Basement Membrane-Targeting Nanoparticles. Small, 2015, 11, 6404-6410.	10.0	8

#	Article	IF	CITATIONS
91	Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors. Biomaterials, 2015, 51, 208-215.	11.4	59
92	Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity. Nanoscale, 2015, 7, 2805-2811.	5.6	32
93	Clinical Translation of Nanomedicine. Chemical Reviews, 2015, 115, 11147-11190.	47.7	619
94	Local iontophoretic administration of cytotoxic therapies to solid tumors. Science Translational Medicine, 2015, 7, 273ra14.	12.4	56
95	Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 386.e1-386.e6.	1.6	15
96	Improving Cancer Chemoradiotherapy Treatment by Dual Controlled Release of Wortmannin and Docetaxel in Polymeric Nanoparticles. ACS Nano, 2015, 9, 8976-8996.	14.6	67
97	Improving DNA double-strand repair inhibitor KU55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery. Nanoscale, 2015, 7, 20211-20219.	5.6	35
98	Polysilsesquioxane nanoparticles for triggered release of cisplatin and effective cancer chemoradiotherapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 31-38.	3.3	71
99	EPR or no EPR? The billion-dollar question. Science Translational Medicine, 2015, 7, .	12.4	37
100	Shutting down the messenger: Antisense treatment for hypertriglyceridemia. Science Translational Medicine, 2015, 7, .	12.4	1
101	Precision cancer medicine: Hype or hope?. Science Translational Medicine, 2015, 7, .	12.4	1
102	Personalized drug tablets with 3D printing. Science Translational Medicine, 2015, 7, .	12.4	3
103	A Randomized Pilot Trial Comparing Position Emission Tomography (PET)-Guided Dose Escalation Radiotherapy to Conventional Radiotherapy in Chemoradiotherapy Treatment of Locally Advanced Nasopharyngeal Carcinoma. PLoS ONE, 2015, 10, e0124018.	2.5	36
104	More than just a fruit: Grapefruit-derived nanovectors deliver cancer drugs. Science Translational Medicine, 2015, 7, .	12.4	0
105	Abstract 1589: Investigation of circulating tumor cells from head and neck cancer patients undergoing radiation therapy: A pilot study. , 2015, , .		0
106	Abstract 5515: Neoadjuvant chemoradiotherapy for rectal cancer with CRLX101, an investigational nanoparticle-drug conjugate with a camptothecin payload. , 2015, , .		0
107	Engineering tumors by rolling sheets. Science Translational Medicine, 2015, 7, .	12.4	0
108	Nanoparticle Formulations of siRNA: The Next Generation of Targeted Therapy for Lymphomas and Leukemias?. EBioMedicine, 2014, 1, 101-102.	6.1	3

#	Article	IF	CITATIONS
109	Receipt of Guideline-Concordant Treatment in Elderly Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2014, 88, 332-338.	0.8	24

Nanoparticles and their applications in cell and molecular biology. Integrative Biology (United) Tj ETQq000 rgBT /Qvgrlock 19 Tf 50 702

111	Differential cell responses to nanoparticle docetaxel and small molecule docetaxel at a sub-therapeutic dose range. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 321-328.	3.3	10
112	Scoring the Recurrence Score in Rectal Cancer. Journal of the National Cancer Institute, 2014, 106, dju295-dju295.	6.3	0
113	Effect of drug release kinetics on nanoparticle therapeutic efficacy and toxicity. Nanoscale, 2014, 6, 2321-2327.	5.6	69
114	Nanotechnology in Radiation Oncology. Journal of Clinical Oncology, 2014, 32, 2879-2885.	1.6	53
115	Current Progress of Aptamer-Based Molecular Imaging. Journal of Nuclear Medicine, 2014, 55, 353-356.	5.0	91
116	Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Database—UNC GOLD. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 32.e1-32.e9.	1.6	8
117	Nanomedicine in chemoradiation. Therapeutic Delivery, 2013, 4, 239-250.	2.2	25
118	Nanoparticles for cancer imaging: The good, the bad, and the promise. Nano Today, 2013, 8, 454-460.	11.9	140
119	Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy. Biomaterials, 2013, 34, 8424-8429.	11.4	101
120	Biotargeted nanomedicines for cancer: six tenets before you begin. Nanomedicine, 2013, 8, 299-308.	3.3	47
121	Preclinical Evaluation of Genexol-PM, a Nanoparticle Formulation of Paclitaxel, as a Novel Radiosensitizer for the Treatment of Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 86, 463-468.	0.8	199
122	Comparison of User-Directed and Automatic Mapping of the Planned Isocenter to Treatment Space for Prostate IGRT. International Journal of Biomedical Imaging, 2013, 2013, 1-12.	3.9	0
123	Application of liposomal technologies for delivery of platinum analogs in oncology. International Journal of Nanomedicine, 2013, 8, 3309.	6.7	67
124	Racial differences in time from prostate cancer diagnosis to treatment initiation. Cancer, 2013, 119, 2486-2493.	4.1	64
125	Improving chemoradiotherapy with nanoparticle therapeutics. Translational Cancer Research, 2013, 2, 320-329.	1.0	25
			_

Biochemical Failure in Prostate Cancer. , 2013, , 807-811.

#	Article	IF	CITATIONS
127	Abstract 4517: Differential cellular response to nanoparticle docetaxel and docetaxel at sub-therapeutic dose range , 2013, , .		0
128	Abstract 4522: Nanoparticle chemosensitization , 2013, , .		0
129	Abstract 4530: Nanoparticle formulation of KU55933 as a potent radiosensitizer , 2013, , .		0
130	Nanoparticle drug delivery: focusing on the therapeutic cargo. Nanomedicine, 2012, 7, 1463-1465.	3.3	8
131	Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8230-8235.	7.1	128
132	Chemoradiotherapy of Human Tumors: Novel Approaches from Nanomedicine. Current Pharmaceutical Design, 2012, 18, 2830-2837.	1.9	14
133	Phase I study of concurrent weekly docetaxel, highâ€dose intensityâ€modulated radiation therapy (IMRT) and androgenâ€deprivation therapy (ADT) for highâ€risk prostate cancer. BJU International, 2012, 110, E721-6.	2.5	17
134	Is Primary Prostate Cancer Treatment Influenced by Likelihood of Extraprostatic Disease? A Surveillance, Epidemiology and End Results Patterns of Care Study. International Journal of Radiation Oncology Biology Physics, 2012, 84, 88-94.	0.8	13
135	Giving failed drugs a fresh chance: a new direction for nanoparticle drug delivery. Expert Review of Medical Devices, 2012, 9, 445-447.	2.8	2
136	Preparation of Neutronâ€Activatable Holmium Nanoparticles for the Treatment of Ovarian Cancer Metastases. Small, 2012, 8, 997-1000.	10.0	17
137	Nanoparticle Delivery of Cancer Drugs. Annual Review of Medicine, 2012, 63, 185-198.	12.2	1,347
138	Folate-Targeted Polymeric Nanoparticle Formulation of Docetaxel Is an Effective Molecularly Targeted Radiosensitizer with Efficacy Dependent on the Timing of Radiotherapy. ACS Nano, 2011, 5, 8990-8998.	14.6	112
139	Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. Biomaterials, 2011, 32, 8548-8554.	11.4	164
140	Formulation of Diblock Polymeric Nanoparticles through Nanoprecipitation Technique. Journal of Visualized Experiments, 2011, , .	0.3	6
141	Antibody conjugated magnetic iron oxide nanoparticles for cancer cell separation in fresh whole blood. Biomaterials, 2011, 32, 9758-9765.	11.4	320
142	Chemoradiation therapy in the management of gastrointestinal malignancies. Future Oncology, 2011, 7, 409-426.	2.4	7
143	Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 586-591.	7.1	489
144	Abstract 382: Evaluation of folate-targeted ChemoRad nanoparticle as intraperitoneal chemoradiotherapy for ovarian cancer. , 2011, , .		0

#	Article	lF	CITATIONS
145	Improving Local Control in Rectal Cancer: Radiation Sensitizers or Radiation Dose?. Journal of Clinical Oncology, 2010, 28, 1623-1624.	1.6	25
146	ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation. Nanomedicine, 2010, 5, 361-368.	3.3	95
147	Nanoparticles for Cancer Diagnosis and Therapy. Nanostructure Science and Technology, 2009, , 209-235.	0.1	5
148	Development of Novel Multifunctional Nanoparticles for Combined Imaging and Targeted Delivery of Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2008, 72, S707.	0.8	0
149	Superparamagnetic Iron Oxide Nanoparticle–Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy. ChemMedChem, 2008, 3, 1311-1315.	3.2	297
150	HERâ€2â€Targeted Nanoparticle–Affibody Bioconjugates for Cancer Therapy. ChemMedChem, 2008, 3, 1839-1843.	3.2	143
151	Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opinion on Biological Therapy, 2008, 8, 1063-1070.	3.1	225
152	Nanoparticles in Medicine: Therapeutic Applications and Developments. Clinical Pharmacology and Therapeutics, 2008, 83, 761-769.	4.7	2,156
153	Nanotechnology and aptamers: applications in drug delivery. Trends in Biotechnology, 2008, 26, 442-449.	9.3	247
154	Self-Assembled Lipidâ^'Polymer Hybrid Nanoparticles: A Robust Drug Delivery Platform. ACS Nano, 2008, 2, 1696-1702.	14.6	851
155	Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2586-2591.	7.1	649
156	ld1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells. Blood, 2008, 112, 1981-1992.	1.4	51
157	Novel Targeted Aptamer-superparamagnetic Iron Oxide Nanoparticle Bioconjugates for Combined Prostate Cancer Imaging and Therapy. International Journal of Radiation Oncology Biology Physics, 2007, 69, S110-S111.	0.8	8
158	Targeted nanoparticles for cancer therapy. Nano Today, 2007, 2, 14-21.	11.9	431
159	Oncogenic Tyrosine Kinases Regulate Proliferative and Survival Signals through Activation of Id1 Blood, 2004, 104, 417-417.	1.4	Ο